Oral Administration of Oxytocin, Like Intranasal Administration, Decreases Top-Down Social Attention.
Intranasal oxytocin
antisaccade task
face emotion
oral oxytocin
social attention
Journal
The international journal of neuropsychopharmacology
ISSN: 1469-5111
Titre abrégé: Int J Neuropsychopharmacol
Pays: England
ID NLM: 9815893
Informations de publication
Date de publication:
17 11 2022
17 11 2022
Historique:
received:
16
04
2022
revised:
20
08
2022
accepted:
01
09
2022
pubmed:
3
9
2022
medline:
22
11
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
The neuropeptide oxytocin (OXT) modulates social cognition by increasing attention to social cues and may have therapeutic potential for impaired social attention in conditions such as autism spectrum disorder. Intranasal administration of OXT is widely used to examine the drug's functional effects in both adults and children and is assumed to enter the brain directly via this route. However, OXT can also influence brain function through increased blood concentrations, and we have recently shown that orally (lingual) administered OXT also modulates neural responses to emotional faces and may be better tolerated for therapeutic use. Here, we examine whether 24 IU OXT administered orally can facilitate social attention. In a randomized, placebo-controlled pharmacologic study, we used a validated emotional antisaccade eye-tracking paradigm to explore the effects of oral OXT on bottom-up and top-down attention processing in 80 healthy male participants. Our findings showed that in terms of top-down attention, oral OXT increased errors for both social (angry, fearful, happy, sad, and neutral emotion faces) and nonsocial stimuli (oval shapes) in the antisaccade condition but increased response latencies only in the social condition. It also significantly reduced post-task state anxiety, but this reduction was not correlated with task performance. A comparison with our previous intranasal OXT study using the same task revealed that both routes have a similar effect on increasing antisaccade errors and response latencies and on reducing state anxiety. Overall, our findings suggest that oral administration of OXT produces similar effects on top-down social attention control and anxiety to intranasal administration and may therefore have therapeutic utility.
Sections du résumé
BACKGROUND
The neuropeptide oxytocin (OXT) modulates social cognition by increasing attention to social cues and may have therapeutic potential for impaired social attention in conditions such as autism spectrum disorder. Intranasal administration of OXT is widely used to examine the drug's functional effects in both adults and children and is assumed to enter the brain directly via this route. However, OXT can also influence brain function through increased blood concentrations, and we have recently shown that orally (lingual) administered OXT also modulates neural responses to emotional faces and may be better tolerated for therapeutic use. Here, we examine whether 24 IU OXT administered orally can facilitate social attention.
METHODS
In a randomized, placebo-controlled pharmacologic study, we used a validated emotional antisaccade eye-tracking paradigm to explore the effects of oral OXT on bottom-up and top-down attention processing in 80 healthy male participants.
RESULTS
Our findings showed that in terms of top-down attention, oral OXT increased errors for both social (angry, fearful, happy, sad, and neutral emotion faces) and nonsocial stimuli (oval shapes) in the antisaccade condition but increased response latencies only in the social condition. It also significantly reduced post-task state anxiety, but this reduction was not correlated with task performance. A comparison with our previous intranasal OXT study using the same task revealed that both routes have a similar effect on increasing antisaccade errors and response latencies and on reducing state anxiety.
CONCLUSIONS
Overall, our findings suggest that oral administration of OXT produces similar effects on top-down social attention control and anxiety to intranasal administration and may therefore have therapeutic utility.
Identifiants
pubmed: 36053298
pii: 6687284
doi: 10.1093/ijnp/pyac059
pmc: PMC9670742
doi:
Substances chimiques
Oxytocin
50-56-6
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
912-923Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of CINP.
Références
Neuropsychologia. 2009 Jan;47(1):248-57
pubmed: 18706434
Horm Behav. 2020 Feb;118:104613
pubmed: 31654673
Cogn Emot. 2016;30(4):700-12
pubmed: 25899613
Exp Brain Res. 2005 Mar;162(1):63-9
pubmed: 15551081
Psychother Psychosom. 2022;91(5):335-347
pubmed: 35545057
Biol Psychiatry. 2016 Apr 15;79(8):693-705
pubmed: 25499958
Mol Psychiatry. 2021 Jan;26(1):80-91
pubmed: 32807845
Behav Res Methods. 2009 Nov;41(4):1149-60
pubmed: 19897823
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7650-4
pubmed: 27325780
Neuroimage. 2017 Nov 15;162:127-137
pubmed: 28877512
Neuropsychologia. 2020 Mar 2;139:107360
pubmed: 31982482
Trends Neurosci. 2012 Nov;35(11):649-59
pubmed: 22974560
Nat Rev Neurosci. 2004 Mar;5(3):218-28
pubmed: 14976521
Brain. 2022 Apr 18;145(2):490-499
pubmed: 35067719
Psychoneuroendocrinology. 2016 Jul;69:180-8
pubmed: 27107209
Mol Psychiatry. 2016 Sep;21(9):1225-31
pubmed: 26503762
PLoS One. 2014 Feb 11;9(2):e86474
pubmed: 24523861
Psychother Psychosom. 2022;91(4):253-264
pubmed: 35086102
Autism Res. 2019 Oct;12(10):1529-1540
pubmed: 31369217
N Engl J Med. 2021 Oct 14;385(16):1462-1473
pubmed: 34644471
Cogn Emot. 2020 Dec;34(8):1746-1752
pubmed: 32746726
Trends Cogn Sci. 2012 Apr;16(4):231-9
pubmed: 22425667
Exp Physiol. 2000 Mar;85 Spec No:111S-124S
pubmed: 10795913
Nat Commun. 2020 Jun 3;11(1):2783
pubmed: 32494001
Nat Commun. 2020 Mar 3;11(1):1160
pubmed: 32127545
Psychopharmacology (Berl). 2006 Apr;185(2):218-25
pubmed: 16418825
Neuropsychopharmacology. 2003 Jan;28(1):193-8
pubmed: 12496956
Transl Psychiatry. 2021 Feb 4;11(1):94
pubmed: 33542175
Prog Neurobiol. 2022 Apr;211:102239
pubmed: 35122880
Peptides. 2020 Jun;128:170312
pubmed: 32298773
Commun Biol. 2020 Feb 13;3(1):70
pubmed: 32054984
Mol Autism. 2020 Apr 9;11(1):24
pubmed: 32272970
Annu Rev Psychol. 2014;65:17-39
pubmed: 24050183
Exp Psychol. 2009;56(1):48-55
pubmed: 19261578
Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8119-8124
pubmed: 28696286
Biol Psychiatry. 2016 Feb 1;79(3):194-202
pubmed: 26321019
Exp Brain Res. 2002 Nov;147(1):53-63
pubmed: 12373369
J Abnorm Psychol. 1988 Aug;97(3):346-53
pubmed: 3192830
Curr Top Behav Neurosci. 2018;35:321-348
pubmed: 28864976
Soc Neurosci. 2019 Oct;14(5):594-607
pubmed: 30378456
J Pharm Pharmacol. 1995 Jul;47(7):571-5
pubmed: 8568623
Neuropsychopharmacology. 2018 Jan;43(2):294-301
pubmed: 28836577
Neuropsychologia. 2011 Apr;49(5):1146-1153
pubmed: 21241717
J Educ Psychol. 1969 Oct;60(5):343-50
pubmed: 5364288
Mol Psychiatry. 2020 Aug;25(8):1849-1858
pubmed: 29955161
Sci Rep. 2017 Aug 11;7(1):7883
pubmed: 28801574
Transl Psychiatry. 2020 May 12;10(1):142
pubmed: 32398642
Neurosci Biobehav Rev. 2021 Mar;122:18-27
pubmed: 33400920
Transl Psychiatry. 2021 Jul 10;11(1):388
pubmed: 34247185
Front Behav Neurosci. 2015 Sep 17;9:245
pubmed: 26441574
Psychophysiology. 2021 Sep;58(9):e13852
pubmed: 34032304
Psychol Med. 2020 Dec 04;:1-10
pubmed: 33272333
Psychoneuroendocrinology. 2019 Oct;108:62-69
pubmed: 31229634
Emotion. 2007 May;7(2):336-53
pubmed: 17516812
Biol Psychol. 2013 Dec;94(3):556-61
pubmed: 24161800
Biol Psychiatry. 2010 Apr 1;67(7):692-4
pubmed: 19897177
Pharmaceutics. 2022 Jan 29;14(2):
pubmed: 35214056
Dev Psychopathol. 2019 Aug;31(3):859-869
pubmed: 30968800
Front Neurosci. 2022 May 12;16:852484
pubmed: 35645716
Biol Psychiatry. 2017 Dec 15;82(12):885-894
pubmed: 28629540
Biol Psychiatry. 2007 Feb 15;61(4):498-503
pubmed: 16904652
Psychoneuroendocrinology. 2021 Nov;133:105412
pubmed: 34537624
Front Pharmacol. 2021 Apr 20;12:652473
pubmed: 33959017
Sci Transl Med. 2019 May 8;11(491):
pubmed: 31043522
Psychophysiology. 2012 Jan;49(1):128-37
pubmed: 22092248
Psychoneuroendocrinology. 2017 Jul;81:52-62
pubmed: 28412582
Brain Cogn. 2012 Apr;78(3):257-67
pubmed: 22289426